PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28492544-2	2017	Our previous study found that halofuginone (HF) exerts anticancer activity in colorectal cancer (CRC) by downregulating Akt/mTORC1 (mechanistic target of rapamycin complex 1) signaling pathway.	halofuginone	30-42	CREB regulated transcription coactivator 1	Mus musculus	124-130	
26160839-0	2015	Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism.	halofuginone	0-12	CREB regulated transcription coactivator 1	Mus musculus	74-80	
26160839-2	2015	Here, we present for the first time that halofuginone (HF) treatment inhibits colorectal cancer (CRC) growth both in vitro and in vivo through regulation of Akt/mTORC1 signaling pathway.	halofuginone	41-53	CREB regulated transcription coactivator 1	Mus musculus	161-167